Australian biotech spinoff to develop drugs

The Australian diagnostics company HealthLinx is spinning off two therapies in clinical development into a new company--Proaegis Biosciences--which will hit the road in search of $4 million in fresh funding. HealthLinx will spin off CR014 for Acute Respiratory Distress Syndrome and Follistatin for ulcerative colitis.

"Expressions of interest for the remaining $4 million have already been received, and it is anticipated that the balance of the funds will be secured from sophisticated investors by early 2008," says HealthLinx managing director Nick Gatsios.

- see this release for more
- here's the report from The Age

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.